Lomvastomig

DB19060InvestigationalProtein Based Therapies

Lomvastomig is under investigation in clinical trial NCT04785820 (A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the...

Mechanism: Pharmacologically active on Programmed cell death protein 1 and Hepatitis A virus cellular receptor 2
Curator reviewed
Also known as: Anti-pd-1/tim-3 bispecific antibody ro7121661
Code names: RG7769 · RO-7121661

Resolves to

Compound

UNII9GAH9VG7IPCAS2648840-52-0

Targets

Q15116PDCD1Q8TDQ0HAVCR2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lomvastomig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account